Augmented Depression Therapy (ADepT) Case Series

This research study plans to examine the use of Augmented Depression Therapy (ADepT) in order to evaluate what patients think about ADepT and how well it works. ADepT is a type of therapy that builds wellbeing and is being provided to you as standard of care.

ADepT treatment consists of 15 therapy sessions (typically provided weekly) with each session lasting around 60 minutes. Following these sessions, you can receive five optional booster sessions over the next 12 months with each of these lasting around 60 minutes. Ultimately, the timing and duration of these sessions will be determined between you and your provider and scheduled accordingly.

As part of this study you will be randomized (randomly assigned) to different research assessment lengths before the start of treatment and then will complete assessments for the 12 months following the end of the weekly portion of ADepT treatment. The length of your participation will be between 70 weeks to 82 weeks.

Study Overview

• Status: Not yet recruiting
• Conditions: Depression / Major Depressive Disorder
• Intervention / Treatment: Behavioral: Augmented Depression Therapy (ADepT)

• Study Type: Interventional
• Enrollment (Estimated): 40
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Jay Fournier, Ph.D.; Phone Number: 614-814-6485; Email: Jay.Fournier@osumc.edu

Study Locations

• United States
  • Ohio
    • Columbus, Ohio, United States, 43214
      • The Ohio State University Wexner Medical Center
      • Contact: Jay Fournier, PhD; Phone Number: 614-814-6485; Email: jay.fournier@osumc.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Aged 18 -65
2. Currently experiencing a major depressive episode based on the Quick Structured Clinical Interview for DSM-5 Disorders (QuickSCID-5; First & Williams, 2021)
3. Scoring > 10 on the PHQ-9
4. Have sufficient knowledge of written and spoken English to provide consent and utilize therapy resources and take assessment measures throughout the protocol without the assistance of a translator.

Exclusion Criteria:

1. Diagnosis of a psychotic or bipolar disorder
2. History of learning disabilities or organic brain change (e.g., from injury or from neurological disorders)
3. Active alcohol or substance use disorder or level of use that would interfere with ability to engage in ADepT treatment
4. Current marked risk to self (self-harm or suicidal ideation) that cannot be managed safely within the ADepT treatment frame
5. Patients cannot be enrolled while they are currently receiving psychotherapy from a different provider in line with current clinic policy and APA ethical guidelines. The possibility of switching providers/treatments will be addressed following established departmental policies and procedures, transcranial magnetic stimulation, ketamine, esketamine, or electroconvulsive therapy. Patients receiving a stable dose of an antidepressant agent will be considered eligible.
6. Presence of another psychiatric disorder judged to be primary

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 3 week baseline + ADepT; Baseline assessments will be made weekly for 3 weeks, followed by a standard course of ADepT.	Behavioral: Augmented Depression Therapy (ADepT); ADepT is a solution-focused behavioral health intervention that blends techniques from cognitive, behavioral, and acceptance-based treatments to help patients manage symptoms of depression and increase wellbeing. It consists of 15 acute treatment sessions and up to 5 booster sessions.
Experimental: 4 week baseline + ADepT; Baseline assessments will be made weekly for 4 weeks, followed by a standard course of ADepT.	Behavioral: Augmented Depression Therapy (ADepT); ADepT is a solution-focused behavioral health intervention that blends techniques from cognitive, behavioral, and acceptance-based treatments to help patients manage symptoms of depression and increase wellbeing. It consists of 15 acute treatment sessions and up to 5 booster sessions.
Experimental: 5 week baseline + ADepT; Baseline assessments will be made weekly for 5 weeks, followed by a standard course of ADepT.	Behavioral: Augmented Depression Therapy (ADepT); ADepT is a solution-focused behavioral health intervention that blends techniques from cognitive, behavioral, and acceptance-based treatments to help patients manage symptoms of depression and increase wellbeing. It consists of 15 acute treatment sessions and up to 5 booster sessions.
Experimental: 6 week baseline + ADepT; Baseline assessments will be made weekly for 6 weeks, followed by a standard course of ADepT.	Behavioral: Augmented Depression Therapy (ADepT); ADepT is a solution-focused behavioral health intervention that blends techniques from cognitive, behavioral, and acceptance-based treatments to help patients manage symptoms of depression and increase wellbeing. It consists of 15 acute treatment sessions and up to 5 booster sessions.
Experimental: 7 week baseline + ADepT; Baseline assessments will be made weekly for 7 weeks, followed by a standard course of ADepT.	Behavioral: Augmented Depression Therapy (ADepT); ADepT is a solution-focused behavioral health intervention that blends techniques from cognitive, behavioral, and acceptance-based treatments to help patients manage symptoms of depression and increase wellbeing. It consists of 15 acute treatment sessions and up to 5 booster sessions.
Experimental: 8 week baseline + ADepT; Baseline assessments will be made weekly for 8 weeks, followed by a standard course of ADepT.	Behavioral: Augmented Depression Therapy (ADepT); ADepT is a solution-focused behavioral health intervention that blends techniques from cognitive, behavioral, and acceptance-based treatments to help patients manage symptoms of depression and increase wellbeing. It consists of 15 acute treatment sessions and up to 5 booster sessions.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Acceptability	Patient ratings of treatment acceptability	From enrollment to the end of treatment at 82 weeks
Attrition	Patient attendance records	From enrollment to the end of treatment at 82 weeks.
Adverse Events	Self-reported adverse events	From enrollment to the end of treatment at 82 weeks.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Montgomery-Asberg Depression Rating Scale (MADRS)	The MADRS is a clinician-administered, 10-item assessment tool used to measure the severity of depressive symptoms and monitor changes in depression over time. Min=0, Max=60, higher scores indicate worse depression.	From enrollment to the end of treatment at 82 weeks.
Patient Health Questionnaire - 9 Item Version (PHQ-9)	The PHQ-9 is a 9-item self-report measure of depression severity. Min=0, Max=27, higher scores indicate worse depression.	From enrollment to the end of treatment at 82 weeks.
Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)	The WEMWBS is a 14-item self-report questionnaire designed to measure positive mental wellbeing, including emotional, psychological, and social functioning. Min=14, Max=70, higher scores indicate higher levels of wellbeing.	From enrollment to the end of treatment at 82 weeks.

Collaborators and Investigators

• Sponsor: Ohio State University

Study record dates

Study Major Dates

• Study Start (Estimated): August 1, 2026
• Primary Completion (Estimated): August 31, 2028
• Study Completion (Estimated): December 31, 2028

Study Registration Dates

• First Submitted: July 23, 2026
• First Submitted That Met QC Criteria: July 28, 2026
• First Posted (Actual): July 29, 2026

Study Record Updates

• Last Update Posted (Actual): July 29, 2026
• Last Update Submitted That Met QC Criteria: July 28, 2026
• Last Verified: July 1, 2026

More Information

Terms related to this study

• Keywords: Depression; Major Depressive Disorder; Major Depressive Episode
• Additional Relevant MeSH Terms: Mental Disorders; Behavioral Symptoms; Mood Disorders; Depressive Disorder; Behavior; Depression; Depressive Disorder, Major
• Other Study ID Numbers: 20251473

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Only IRB approved personnel will have access to identifiable data. De-identified data may be shared with other research groups examining similar questions or as a requirement for publication in certain journals.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No